Hometown hero, George Springer, keeps in top shape thanks to a Houston organization's technology. Photo by Ezra Shaw/Getty Images

As the Houston Astros head into game three of the World Series tonight, two players taking the field can credit a West Houston fitness training facility's mobile app for keeping them in shape both during the off season and between games.

Fairchild Sports Performance has been in the professional, collegiate, and amateur sports training business since 2012. A couple years ago, Founder Ben Fairchild decided he wanted to take things to the next level.

"The FSP app is for anybody who has a body," Fairchild says. "We want to find solutions for long-term health and fitness challenges for people of all walks of life."

While the app and the training is for everyone, Fairchild's app has been attractive to professionals. FSP has 15 professional athletes as clients. George Springer, right fielder for the Houston Astros, and Anthony Rendon, third baseman for the Washington Nationals, train with Fairchild — and they both rely on the app to tell them what their bodies need.

The app, which is run by FSP Online Director Steven Hamner, allows the athletes to log and track their progress, view workout demonstrations, and access Fairchild's fitness instruction from anywhere.

In the two seasons the app has been live, FSP's MLB clients have achieved career highs in different categories, All-Star game appearances, MLB debuts, and World Series wins.

"The in-season program and philosophy is based around having a training program year-round as opposed to just a few months out of the year in the offseason," explains Hamner. "In having a program year round it enables us to constantly progress through out the year with the offseason and in-season programs looking completely differently as it relates to frequency, volume, and intensity in the weight room."

While keeping in shape is key during the off season, the app is helpful to these professional athletes during the season too. And, since they have everything they need at their fingertips, it's convenient for away games as they travel across the country.

"The goal for training in-season is to facilitate recovery throughout the season, limit fatigue as much as possible, especially towards the end of the season, and set athletes up for a positive starting place in the offseason," says Hamner. "This will lead to a better physical state going into the following spring training. We always have the long-term best interest of the player in mind, this is their career earning potential, which is tied to their health and performance."

The sports technology business is booming, and Houston has become a hotbed for startups creating technology — like Truss, Integrated Bionics, and Win-Win. Fairchild says he has some interest in the power of data and technology for sports performance, but he won't be going overboard.

"Data gathering possibilities are enormous in this day and age," Fairchild tells InnovationMap. "However, data is only as valuable as one's ability to make use of the results and effect change. That said, we try to get the most valuable measuring tools, be it for evaluation of pitching biomechanics or rate of force delivery on an exercise, to help shape workouts. We don't get carried away with tech — we trust the eyes of experienced people. But we use tech to the level that is beneficial.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”